Archana Raman

Archana Raman

Auto-generated profile, based on publicly available information

Archana Raman

Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia (F.L., B.P., M.A.-S., J. Wu, A.R., J. Wahba, A.V., C.L., A.A., K.A.K., K.S.).

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JWJunnan Wu
Junnan Wu
ARArchana Raman
Archana Raman
NCNathan J. Coffey
Nathan J. Coffey
XSXin Sheng
Xin Sheng
JWJoseph Wahba
Joseph Wahba
KSKatalin Susztak
Katalin Susztak
Coding variants in apolipoprotein L1 (APOL1), termed G1 and G2, can explain most excess kidney disease risk in African Americans; however, the molecular pathways of APOL1-induced kidney dysfunction remain poorly understood. Here, we report that expression of G2 APOL1 in the podocytes of Nphs1rtTA/TRE-G2APOL1 (G2APOL1) mice leads to early activation of the cytosolic nucleotide sensor, stimulator of interferon genes (STING), and the NLR family pyrin domain–containing 3 (NLRP3) inflammasome. STING and NLRP3 expression was increased in podocytes from patients with high-risk APOL1 genotypes, and expression of APOL1 correlated with caspase-1 and gasdermin D (GSDMD) levels. To demonstrate the role of NLRP3 and STING in APOL1-associated kidney disease, we generated transgenic mice with the G2 APOL1 risk variant and genetic deletion of Nlrp3 (G2APOL1/Nlrp3 KO), Gsdmd (G2APOL1/Gsdmd KO), and STING (G2APOL1/STING KO). Knockout mice displayed marked reduction in albuminuria, azotemia, and kidney fibrosis compared with G2APOL1 mice. To evaluate the therapeutic potential of targeting NLRP3, GSDMD, and STING, we treated mice with MCC950, disulfiram, and C176, potent and selective inhibitors of NLRP3, GSDMD, and STING, respectively. G2APOL1 mice treated with MCC950, disulfiram, and C176 showed lower albuminuria and improved kidney function even when inhibitor treatment was initiated after the development of albuminuria.

1 January 2010 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
GKGino A. Kurian
Gino A. Kurian
SSSrilalitha Suryanarayanan
Srilalitha Suryanarayanan
ARArchana Raman
Archana Raman
JPJose Padikkala
Jose Padikkala
This study aims to evaluate the antioxidant potential of the ethyl acetate extract of Desmodium gangeticum root for cardioprotection from ischemia reperfusion-induced oxidative stress.

29 April 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
XGXiangchen Gu
Xiangchen Gu
ARArchana Raman
Archana Raman
KSKatalin Susztak
Katalin Susztak
Acute kidney injury (AKI) is one of the most important risk factors for chronic and progressive kidney disease, leading to end-stage kidney failure. Tubule epithelial regeneration leads to the resolution of renal failure in AKI. Failure of tubule epithelial regeneration leads to concomitant hypoxia from loss of microcirculation, which serves as a critical factor leading to chronic kidney disease. In this issue of the JCI, Li et al. show that hypoxia activates the stress-responsive transcription factor FoxO3. Increased FoxO3 protein abundance leads to alterations in tubular epithelial autophagy and metabolism, highlighting an important mechanism causing permanent renal damage even after an acute injury.

10 February 2026 in Circulation
Verified
Journal Article
Open access
FLFang Li
Fang Li
BPBibek Poudel
Bibek Poudel
MAMagaiver Andrade-Silva
Magaiver Andrade-Silva
JWJunnan Wu
Junnan Wu
ARArchana Raman
Archana Raman
KSKatalin Susztak
Katalin Susztak
BACKGROUND: Black people bear a disproportionate burden of hypertension and hypertension-attributed chronic kidney disease. A role of apolipoprotein L1 ( APOL1 ) risk variants (RVs; G1 and G2) in these conditions has been proposed, but genetic and observational studies have shown inconsistent results. METHODS: Here, we investigated the causal role of APOL1 RVs using patient samples, transgenic animal models, and in vitro primary cellular experiments. RESULTS: In the human kidney, APOL1 was highly expressed by glomerular podocytes and endothelial cells. Mice with podocyte-specific expression of the APOL1 RV (G2 APOL1 ), but not those with the reference allele (G0), developed severe secondary hypertension after albuminuria and kidney disease. Mice expressing endothelium-specific G2 APOL1 RVs developed mild hypertension with aging, which was exacerbated after unilateral nephrectomy and subsequent high-salt diet feeding. This condition was associated with a slight alteration in kidney function. In vitro and in vivo experiments demonstrated that the APOL1 RV activates the cytosolic nucleotide sensor STING (stimulator of interferon genes), leading to increased production of endothelin 1. Notably, mice with endothelium-specific STING knockout or those treated with an endothelin inhibitor showed protection from G2 APOL1 RV–mediated hypertension. CONCLUSIONS: These findings indicate a role of G2 APOL1 in hypertension development through STING and endothelin 1 activation, offering new precision therapeutics for addressing hypertension in Black people carrying APOL1 RVs.